[
  {
    "ts": "2025-11-19T14:48:00+00:00",
    "headline": "Knee Replacement Surgery Market Analysis Report 2025-2035: Stryker, Zimmer Biomet, B. Braun, and DePuy Synthes Lead Innovations by Continually Innovating and Improving Patient Outcomes",
    "summary": "Knee replacement surgery effectively addresses severe knee conditions like osteoarthritis, offering pain relief and improved mobility. The procedure sees high demand due to rising osteoarthritis among the aging population, especially as global lifespans increase. Although the surgery significantly enhances life quality, challenges such as high costs and lengthy recovery persist, affecting both patients and healthcare systems. The competitive market witnesses innovation from key players like Stry",
    "url": "https://finance.yahoo.com/news/knee-replacement-surgery-market-analysis-144800644.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "b9aa2091-c1b4-3e6a-8f95-e87f7bec2344",
      "content": {
        "id": "b9aa2091-c1b4-3e6a-8f95-e87f7bec2344",
        "contentType": "STORY",
        "title": "Knee Replacement Surgery Market Analysis Report 2025-2035: Stryker, Zimmer Biomet, B. Braun, and DePuy Synthes Lead Innovations by Continually Innovating and Improving Patient Outcomes",
        "description": "",
        "summary": "Knee replacement surgery effectively addresses severe knee conditions like osteoarthritis, offering pain relief and improved mobility. The procedure sees high demand due to rising osteoarthritis among the aging population, especially as global lifespans increase. Although the surgery significantly enhances life quality, challenges such as high costs and lengthy recovery persist, affecting both patients and healthcare systems. The competitive market witnesses innovation from key players like Stry",
        "pubDate": "2025-11-19T14:48:00Z",
        "displayTime": "2025-11-19T14:48:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/knee-replacement-surgery-market-analysis-144800644.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/knee-replacement-surgery-market-analysis-144800644.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "SYK"
            },
            {
              "symbol": "ZBH"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-19T13:53:00+00:00",
    "headline": "BAYRY Obtains Approval for Hormone Free VMS Treatment Lynkuet in the EU",
    "summary": "Bayer wins EU approval for Lynkuet, expanding its pharma portfolio with a hormone-free treatment for moderate to severe vasomotor symptoms",
    "url": "https://finance.yahoo.com/news/bayry-obtains-approval-hormone-free-135300684.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "8ca113b4-07d7-3a04-89b7-ffc73358ef44",
      "content": {
        "id": "8ca113b4-07d7-3a04-89b7-ffc73358ef44",
        "contentType": "STORY",
        "title": "BAYRY Obtains Approval for Hormone Free VMS Treatment Lynkuet in the EU",
        "description": "",
        "summary": "Bayer wins EU approval for Lynkuet, expanding its pharma portfolio with a hormone-free treatment for moderate to severe vasomotor symptoms",
        "pubDate": "2025-11-19T13:53:00Z",
        "displayTime": "2025-11-19T13:53:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/50c06d1d19c16cb71d6cb49028119372",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5pnU3NQ.800lSpcRBKjZNg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/50c06d1d19c16cb71d6cb49028119372.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/W2_ZZ2Pl7OVNL4tXoICDoQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/50c06d1d19c16cb71d6cb49028119372.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bayry-obtains-approval-hormone-free-135300684.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bayry-obtains-approval-hormone-free-135300684.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BAYRY"
            },
            {
              "symbol": "BAYZF"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "BAYN.DE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-19T13:02:00+00:00",
    "headline": "Will Ion Platform's 52% Growth Make It ISRG's Next Growth Engine?",
    "summary": "Intuitive Surgical's Ion platform represents robust growth potential with strong procedure growth. Clinical trial data demonstrate superiority in diagnostic yield.",
    "url": "https://finance.yahoo.com/news/ion-platforms-52-growth-isrgs-130200532.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "dde3d0d6-562f-3dd0-ab06-652a6eae421d",
      "content": {
        "id": "dde3d0d6-562f-3dd0-ab06-652a6eae421d",
        "contentType": "STORY",
        "title": "Will Ion Platform's 52% Growth Make It ISRG's Next Growth Engine?",
        "description": "",
        "summary": "Intuitive Surgical's Ion platform represents robust growth potential with strong procedure growth. Clinical trial data demonstrate superiority in diagnostic yield.",
        "pubDate": "2025-11-19T13:02:00Z",
        "displayTime": "2025-11-19T13:02:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/ffe56c6b40972cd987bbb0cf256ae119",
          "originalWidth": 620,
          "originalHeight": 413,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ly2eKWIt2DGVNvSZ_c1.OQ--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ffe56c6b40972cd987bbb0cf256ae119.cf.webp",
              "width": 620,
              "height": 413,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Jcy0r8Ec0Arq0Msc4P7F2w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ffe56c6b40972cd987bbb0cf256ae119.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/ion-platforms-52-growth-isrgs-130200532.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/ion-platforms-52-growth-isrgs-130200532.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ISRG"
            },
            {
              "symbol": "MDT"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-19T14:08:00+00:00",
    "headline": "AbbVie Stock Rebounds After Q3 Dip: Time to Buy, Hold or Sell?",
    "summary": "ABBV rebounds after its Q3 dip as strong immunology and neuroscience growth offset Humira erosion and aesthetics weakness.",
    "url": "https://finance.yahoo.com/news/abbvie-stock-rebounds-q3-dip-140800339.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "ae51e31e-ef42-301a-8add-32efb43b0505",
      "content": {
        "id": "ae51e31e-ef42-301a-8add-32efb43b0505",
        "contentType": "STORY",
        "title": "AbbVie Stock Rebounds After Q3 Dip: Time to Buy, Hold or Sell?",
        "description": "",
        "summary": "ABBV rebounds after its Q3 dip as strong immunology and neuroscience growth offset Humira erosion and aesthetics weakness.",
        "pubDate": "2025-11-19T14:08:00Z",
        "displayTime": "2025-11-19T14:08:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/65d4d9838ddb692fbe578219ce60c69d",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OAiu5He0SiZzKJ7weu9Org--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/65d4d9838ddb692fbe578219ce60c69d.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xHxlTKesMnS_SkMo1hl1jw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/65d4d9838ddb692fbe578219ce60c69d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-stock-rebounds-q3-dip-140800339.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-stock-rebounds-q3-dip-140800339.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-19T14:00:05+00:00",
    "headline": "Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finance.yahoo.com/news/johnson-johnson-jnj-attracting-investor-140005461.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "1187f040-0305-32fc-ab74-7e32006565a1",
      "content": {
        "id": "1187f040-0305-32fc-ab74-7e32006565a1",
        "contentType": "STORY",
        "title": "Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know",
        "description": "",
        "summary": "Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
        "pubDate": "2025-11-19T14:00:05Z",
        "displayTime": "2025-11-19T14:00:05Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/023168c7ea091c342492be3899b280af",
          "originalWidth": 900,
          "originalHeight": 618,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AH29CN1G1bp_AgmMAtiHlQ--~B/aD02MTg7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/023168c7ea091c342492be3899b280af.cf.webp",
              "width": 900,
              "height": 618,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xcYKn6Tda5Sy52WTJQhMtA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/023168c7ea091c342492be3899b280af.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-jnj-attracting-investor-140005461.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-jnj-attracting-investor-140005461.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "^SPX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-19T15:52:00+00:00",
    "headline": "Merck Stock Rise as New PAH Drug Winrevair Meets Goal in Another Study",
    "summary": "MRK's Winrevair hits its phase II goal in patients with CpcPH tied to HFpEF, setting up phase III plans and a potential path to broader use. Stock up.",
    "url": "https://finance.yahoo.com/news/merck-stock-rise-pah-drug-155200590.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "a2a26fa5-504e-3e41-8a8f-1626300634b0",
      "content": {
        "id": "a2a26fa5-504e-3e41-8a8f-1626300634b0",
        "contentType": "STORY",
        "title": "Merck Stock Rise as New PAH Drug Winrevair Meets Goal in Another Study",
        "description": "",
        "summary": "MRK's Winrevair hits its phase II goal in patients with CpcPH tied to HFpEF, setting up phase III plans and a potential path to broader use. Stock up.",
        "pubDate": "2025-11-19T15:52:00Z",
        "displayTime": "2025-11-19T15:52:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/1b28b8f55ab25205feceb1a2771a2b3a",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RRg0vYpNavphT7S8O9jT7w--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1b28b8f55ab25205feceb1a2771a2b3a.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hIkvgr9e5vaptAEV_vkcVg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1b28b8f55ab25205feceb1a2771a2b3a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-stock-rise-pah-drug-155200590.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-stock-rise-pah-drug-155200590.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-19T17:24:46+00:00",
    "headline": "Why Johnson & Johnson's Share Price Is Popping This Month",
    "summary": "Johnson & Johnson had strong Q3 results and reported an important acquisition.",
    "url": "https://www.fool.com/investing/2025/11/19/why-johnson-johnson-share-price-popping-november/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "b07a1d8a-3c5a-3b94-99f8-28b3b64cbf81",
      "content": {
        "id": "b07a1d8a-3c5a-3b94-99f8-28b3b64cbf81",
        "contentType": "STORY",
        "title": "Why Johnson & Johnson's Share Price Is Popping This Month",
        "description": "",
        "summary": "Johnson & Johnson had strong Q3 results and reported an important acquisition.",
        "pubDate": "2025-11-19T17:24:46Z",
        "displayTime": "2025-11-19T17:24:46Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/1b83ce22883ee08ca72f38c8c60da869",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "Pills sitting on x-ray prints.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ylKiRslOmVVCNXTvnHZCFA--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/1b83ce22883ee08ca72f38c8c60da869.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/O0U.JUqMeD6BFEW2GvZuQw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/1b83ce22883ee08ca72f38c8c60da869.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/11/19/why-johnson-johnson-share-price-popping-november/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-johnson-johnsons-share-price-172446666.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-19T17:36:12+00:00",
    "headline": "Why big pharma is teaming up with AI giants to speed up drug discovery and make work easier for health care workers",
    "summary": "Eli Lilly and J&J recently announced partnerships with AI chipmaker Nvidia, pointing to a broader trend of tie-ups to advance drug discovery and improve workflows.",
    "url": "https://finance.yahoo.com/news/why-big-pharma-teaming-ai-173612559.html",
    "source": "Fortune",
    "provider": "yfinance",
    "raw": {
      "id": "08367ad6-8d74-37de-8472-404e1894c300",
      "content": {
        "id": "08367ad6-8d74-37de-8472-404e1894c300",
        "contentType": "STORY",
        "title": "Why big pharma is teaming up with AI giants to speed up drug discovery and make work easier for health care workers",
        "description": "",
        "summary": "Eli Lilly and J&J recently announced partnerships with AI chipmaker Nvidia, pointing to a broader trend of tie-ups to advance drug discovery and improve workflows.",
        "pubDate": "2025-11-19T17:36:12Z",
        "displayTime": "2025-11-19T17:36:12Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/fortune_175/33f417597750237fd67ec930559a05a3",
          "originalWidth": 2048,
          "originalHeight": 1338,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fbQbpC7NOXNl5XvtcH6XFQ--~B/aD0xMzM4O3c9MjA0ODthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/fortune_175/33f417597750237fd67ec930559a05a3.cf.webp",
              "width": 2048,
              "height": 1338,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lsny3YXcNHszf.EelKnZtA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/fortune_175/33f417597750237fd67ec930559a05a3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Fortune",
          "url": "http://fortune.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-big-pharma-teaming-ai-173612559.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-big-pharma-teaming-ai-173612559.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-19T20:59:08+00:00",
    "headline": "Sector Update: Health Care Stocks Softer Late Afternoon",
    "summary": "Health care stocks fell late Wednesday afternoon with the NYSE Health Care Index easing 0.1% and the",
    "url": "https://finance.yahoo.com/news/sector-health-care-stocks-softer-205908101.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "7aa18ef0-9213-3d2a-81fe-18746163c1f1",
      "content": {
        "id": "7aa18ef0-9213-3d2a-81fe-18746163c1f1",
        "contentType": "STORY",
        "title": "Sector Update: Health Care Stocks Softer Late Afternoon",
        "description": "",
        "summary": "Health care stocks fell late Wednesday afternoon with the NYSE Health Care Index easing 0.1% and the",
        "pubDate": "2025-11-19T20:59:08Z",
        "displayTime": "2025-11-19T20:59:08Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/sector-health-care-stocks-softer-205908101.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/sector-health-care-stocks-softer-205908101.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "AGIO"
            },
            {
              "symbol": "XLV"
            },
            {
              "symbol": "MRNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-19T15:38:00+00:00",
    "headline": "Why GRAIL Stock Could Be Biotech’s Next Big Breakout",
    "summary": "Explore insider buying signals, a promising cancer detection biotech, and why the American Dream is still achievable—even in a down market.",
    "url": "https://www.marketbeat.com/originals/why-grail-stock-could-be-biotechs-next-big-breakout/?utm_source=yahoofinance&utm_medium=yahoofinance",
    "source": "MarketBeat",
    "provider": "yfinance",
    "raw": {
      "id": "b3f9b3d7-89b5-34b8-a575-d2fac02c152f",
      "content": {
        "id": "b3f9b3d7-89b5-34b8-a575-d2fac02c152f",
        "contentType": "STORY",
        "title": "Why GRAIL Stock Could Be Biotech’s Next Big Breakout",
        "description": "",
        "summary": "Explore insider buying signals, a promising cancer detection biotech, and why the American Dream is still achievable—even in a down market.",
        "pubDate": "2025-11-19T15:38:00Z",
        "displayTime": "2025-11-19T15:38:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketbeat_955/a7576054b9fba267cd3763f62905592c",
          "originalWidth": 1200,
          "originalHeight": 800,
          "caption": "Dripping reagent into test tube with blue liquid.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6aUtHZOG7MHF0wGXtZaPjg--~B/aD04MDA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketbeat_955/a7576054b9fba267cd3763f62905592c.cf.webp",
              "width": 1200,
              "height": 800,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Rvs0b_elk8B.5sbl_olo6A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketbeat_955/a7576054b9fba267cd3763f62905592c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketBeat",
          "url": "https://www.marketbeat.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketbeat.com/originals/why-grail-stock-could-be-biotechs-next-big-breakout/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-grail-stock-could-biotech-153800477.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GRAL"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]